T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
Tennant Co
TNC
$1.19B
| $3.94M | ﹤0.01% |
51,600
| – | – |
|
1477
Monolithic Power Systems
MPWR
$68.4B
| $3.89M | ﹤0.01% |
91,800
-14,000
| -13% | -$543K |
|
|
PLCM
1478
DELISTED
POLYCOM INC
PLCM
| $3.88M | ﹤0.01% |
309,824
+19,600
| +7% | +$249K |
|
1479
Starwood Property Trust
STWD
$6.08B
| $3.85M | ﹤0.01% |
161,900
-417,560
| -72% | -$9.95M |
|
1480
Opko Health
OPK
$1B
| $3.76M | ﹤0.01% |
425,000
+93,000
| +28% | +$812K |
|
1481
John Wiley & Sons Class A
WLY
$2.63B
| $3.69M | ﹤0.01% |
60,870
| – | – |
|
1482
lululemon athletica
LULU
$13.5B
| $3.68M | ﹤0.01% |
91,000
-207,442
| -70% | -$9.46M |
|
|
FL
1483
DELISTED
Foot Locker
FL
| $3.67M | ﹤0.01% |
72,462
-405
| -0.6% | -$19.4K |
|
|
EV
1484
DELISTED
Eaton Vance Corp.
EV
| $3.63M | ﹤0.01% |
95,966
-9,300
| -9% | -$343K |
|
1485
ONE Gas
OGS
$5.09B
| $3.62M | ﹤0.01% |
95,892
+11,600
| +14% | +$424K |
|
|
SPHS
1486
DELISTED
Sophiris Bio, Inc.
SPHS
| $3.61M | ﹤0.01% |
1,613,328
-900
| -0.1% | -$2.66K |
|
1487
Banco Bradesco
BBD
$34.3B
| $3.58M | ﹤0.01% |
628,315
-48,981
| -7% | -$286K |
|
1488
Ashland
ASH
$3.38B
| $3.56M | ﹤0.01% |
67,019
-5,545
| -8% | -$277K |
|
1489
Trinity Industries
TRN
$2.34B
| $3.51M | ﹤0.01% |
111,617
+27,085
| +32% | +$768K |
|
|
ATVI
1490
DELISTED
Activision Blizzard
ATVI
| $3.46M | ﹤0.01% |
155,313
-1,389,236
| -90% | -$28.6M |
|
|
HPTX
1491
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $3.38M | ﹤0.01% |
129,533
+28,841
| +29% | +$741K |
|
1492
Richardson Electronics
RELL
$298M
| $3.37M | ﹤0.01% |
321,550
+1,700
| +0.5% | +$17.4K |
|
|
SHPG
1493
DELISTED
Shire pic
SHPG
| $3.36M | ﹤0.01% |
14,265
-300
| -2% | -$52.2K |
|
|
DRE
1494
DELISTED
Duke Realty Corp.
DRE
| $3.34M | ﹤0.01% |
183,861
+23,500
| +15% | +$411K |
|
1495
Autoliv
ALV
$8.92B
| $3.34M | ﹤0.01% |
43,444
+5,968
| +16% | +$446K |
|
|
SPN
1496
DELISTED
Superior Energy Services, Inc.
SPN
| $3.31M | ﹤0.01% |
9,166
-31,102
| -77% | -$10.3M |
|
1497
Theravance Biopharma
TBPH
$878M
| $3.31M | ﹤0.01% |
+103,896
| New | +$3.13M |
|
1498
Cedar Fair
FUN
$1.71B
| $3.29M | ﹤0.01% |
62,198
-20
| -0% | -$1.04K |
|
1499
TTEC Holdings
TTEC
$79.9M
| $3.28M | ﹤0.01% |
113,090
+4,600
| +4% | +$119K |
|
|
PHLT
1500
DELISTED
Performant Healthcare Inc
PHLT
| $3.27M | ﹤0.01% |
324,300
+19,300
| +6% | +$176K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.